Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)

INTRODUCTION: Preliminary data indicates that proactive therapeutic drug monitoring (TDM) is associated with better outcomes compared with empiric dose escalation and/or reactive TDM, and that pharmacokinetic (PK) modelling can improve the precision of individual dosing schedules in Crohn’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Papamichael, Konstantinos, Jairath, Vipul, Zou, Guangyong, Cohen, Benjamin, Ritter, Timothy, Sands, Bruce, Siegel, Corey, Valentine, John, Smith, Michelle, Vande Casteele, Niels, Dubinsky, Marla, Cheifetz, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977745/
https://www.ncbi.nlm.nih.gov/pubmed/35365535
http://dx.doi.org/10.1136/bmjopen-2021-057656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977745/
https://www.ncbi.nlm.nih.gov/pubmed/35365535
http://dx.doi.org/10.1136/bmjopen-2021-057656

Ejemplares similares